Joshua AM - Search Results

1

Phase I/II Trial of the Combination of ¹⁷⁷Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).

Crumbaker M, Pathmanandavel S, Yam AO, Nguyen A, Ho B, Chan L, Ende JA, Rofe C, Kongrak K, Kwan EM, Azad AA, Sharma S, Pugh TJ, Danesh A, Keane J, Eu P, Joshua AM, Emmett L. Crumbaker M, et al. Among authors: joshua am. Eur Urol Oncol. 2021 Dec;4(6):963-970. doi: 10.1016/j.euo.2020.07.002. Epub 2020 Aug 3. Eur Urol Oncol. 2021. PMID: 32758400 Clinical Trial.

2

Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.

Dhani NC, Emmenegger U, Adams L, Jongstra J, Tannock IF, Sridhar SS, Knox JJ, Day JR, Groskopf J, Joshua AM. Dhani NC, et al. Among authors: joshua am. BJU Int. 2012 Sep;110(6):840-5. doi: 10.1111/j.1464-410X.2011.10922.x. Epub 2012 Feb 7. BJU Int. 2012. PMID: 22313860 Clinical Trial.

3

The changing landscape in metastatic castration-resistant prostate cancer.

Leibowitz-Amit R, Joshua AM. Leibowitz-Amit R, et al. Among authors: joshua am. Curr Opin Support Palliat Care. 2013 Sep;7(3):243-8. doi: 10.1097/SPC.0b013e328362ffef. Curr Opin Support Palliat Care. 2013. PMID: 23817317 Review.

4

Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.

Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, Clayton R, Heng DY, Joshua AM, Chi KN. Azad AA, et al. Among authors: joshua am. Eur Urol. 2015 Mar;67(3):441-7. doi: 10.1016/j.eururo.2014.01.030. Epub 2014 Jan 31. Eur Urol. 2015. PMID: 24508071

5

A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.

Sridhar SS, Joshua AM, Gregg R, Booth CM, Murray N, Golubovic J, Wang L, Harris P, Chi KN. Sridhar SS, et al. Among authors: joshua am. Clin Genitourin Cancer. 2015 Apr;13(2):124-9. doi: 10.1016/j.clgc.2014.06.001. Epub 2014 Jun 8. Clin Genitourin Cancer. 2015. PMID: 24993934 Free PMC article. Clinical Trial.

6

Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.

Leibowitz-Amit R, Seah JA, Atenafu EG, Templeton AJ, Vera-Badillo FE, Alimohamed N, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Leibowitz-Amit R, et al. Among authors: joshua am. Eur J Cancer. 2014 Sep;50(14):2399-407. doi: 10.1016/j.ejca.2014.06.004. Epub 2014 Jul 16. Eur J Cancer. 2014. PMID: 25042152

7

Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone.

Leibowitz-Amit R, Alimohamed N, Vera-Badillo FE, Seah JA, Templeton AJ, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Leibowitz-Amit R, et al. Among authors: joshua am. Prostate. 2014 Oct;74(14):1462-4. doi: 10.1002/pros.22861. Epub 2014 Aug 11. Prostate. 2014. PMID: 25111736

8

A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.

Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN. Azad AA, et al. Among authors: joshua am. Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872. Epub 2014 Aug 29. Prostate. 2014. PMID: 25175831

9

Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.

Leibowitz-Amit R, Templeton AJ, Alibhai SM, Knox JJ, Sridhar SS, Tannock IF, Joshua AM. Leibowitz-Amit R, et al. Among authors: joshua am. J Geriatr Oncol. 2015 Jan;6(1):23-8. doi: 10.1016/j.jgo.2014.09.183. Epub 2014 Oct 7. J Geriatr Oncol. 2015. PMID: 25301537

10

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Ryan CJ, et al. Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16. Lancet Oncol. 2015. PMID: 25601341 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

230 results

Search Page

Filters